Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Alterity Therapeutics Ltd
  6. News
  7. Summary
       AU000000PBT9

ALTERITY THERAPEUTICS LTD

SummaryChartsNewsRatingsCalendarCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Prana Biotechnology : receives A$3.3 million R&D Tax Incentive

03/17/2019 | 07:44pm EST

Prana Biotechnology Ltd (ASX: PBT NASDAQ: PRAN) has today announced that is has received a A$3.3 million cash refund under the Australian Government's R&D Tax Incentive Scheme.

The refund relates to the cost of eligible research and development activities conducted during the 2018 financial year. These funds will be used to further Prana's research and development activities.

The R&D Tax incentive refund will add to Prana's cash position which was reported as A$8.4M at the end of December 2018. As announced on 28 December 2018, Prana entered into a securities purchase agreement for a lead investment by Life Biosciences LLC to raise up to A$44.5 million, subject to shareholder approval at a General Meeting to be held on 5 April 2019.

Disclaimer

Prana Biotechnology Ltd. published this content on 18 March 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 18 March 2019 00:43:06 UTC


ę Publicnow 2019
All news about ALTERITY THERAPEUTICS LTD
06:19aALTERITY THERAPEUTICS : Appendix 4C – Q2 FY22 Quarterly Cash Flow Report - Form 6-K
PU
01/26ALTERITY THERAPEUTICS : Appendix 4C and Quarterly Cash Flow Report
PU
01/06Alterity Therapeutics Wins US Patent to Develop Treatments for Neurodegenerative Disord..
MT
01/06Wall Street Set for Mixed Open After Fed-Induced Retreat
MT
01/06Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Disease..
CI
01/06ALTERITY THERAPEUTICS : Granted New US Patent for Compounds for Neurodegenerative Diseases..
PU
01/05Alterity Therapeutics Jumps 20% After Securing Patent for Compounds to Treat Neurodegen..
MT
01/05ALTERITY THERAPEUTICS : Final Director's Interest Notice - Form 6-K
PU
01/05ALTERITY THERAPEUTICS : to Present at the H.C. Wainwright BIOCONNECT Virtual Conference - ..
PU
01/05ALTERITY THERAPEUTICS : Notification of cessation of securities - ATH - Form 6-K
PU
More news
Analyst Recommendations on ALTERITY THERAPEUTICS LTD
More recommendations
Chart ALTERITY THERAPEUTICS LTD
Duration : Period :
Alterity Therapeutics Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
David A. Stamler Chief Executive Officer
Kathryn J. E. Andrews Chief Financial Officer
Geoffrey Paul Kempler Non-Executive Chairman
Brian Derek Meltzer Independent Non-Executive Director
Peter Ashley Marks Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ALTERITY THERAPEUTICS LTD48.48%33
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784
IQVIA HOLDINGS INC.-17.54%44 443
SEAGEN INC.-20.08%22 592
ICON PUBLIC LIMITED COMPANY-18.28%20 601